Swiss pharmaceuticals giant Novartis says a no-deal Brexit could hurt patients and that it is stockpiling medicines in the UK to help ensure continuity of supply.
This content was published on
1 minute
swissinfo.ch/jc
In a press release on Friday, it said that after the British parliament’s rejection of Prime Minister Theresa May’s Brexit deal, “the risk of UK exiting the EU without a deal is increased and this will be hugely impactful for patients, particularly around the supply and safety of medicines”.
And it called for the British government to take action on medicines.
“It is vital that Government makes minimising disruption to the medicines supply the highest priority as it prepares for a potential hard or disorderly Brexit and ensures cooperation over medicines regulation in this event.”
The pharma giant said it is prioritising measures to ensure that patients in the UK can access medicines produced by Novartis and its Sandoz and Alcon affiliates. It imports some 120 million packs of medicines to the UK from Europe each year, according to the press release.
Novartis also urged the National Health Service and pharmacists in the UK to heed advice not to stockpile medicines, “so supply can be managed centrally, minimising the risk of medicine shortages across the UK”.
Novartis, maker of neurological, immunology and cancer drugs, employs around 1,500 people in the UK.
More
More
Brexit worries to keep Theresa May away from Davos
This content was published on
UK Prime Minister Theresa May, citing domestic concerns, has followed her French and American counterparts by pulling out of this year’s WEF.
Swiss money laundering office registers record number of reports
This content was published on
The Money Laundering Reporting Office Switzerland (MROS) registered a record number of reports of suspicious activity last year.
Two teens accused of planning terror attack released from custody
This content was published on
The Schaffhausen judiciary has released the two teenagers from custody who allegedly planned bomb attacks in Switzerland.
OECD: Sluggish economic activity slowing growth in Switzerland
This content was published on
Sluggish economic activity at the start of the year is weighing on growth in Switzerland, with GDP expected to fall to 1.1% in 2024.
Report finds mistakes which led to Swiss government data breach
This content was published on
Mistakes were made by both the government and internet company Xplain in the case of a criminal cyber-attack on the Bern-based IT business.
Swiss government wants better gender balance in federal administration
This content was published on
New Swiss government personnel management targets say there must be even more female managers in the federal administration.
Swiss national science foundation funded over 5,000 projects in 2023
This content was published on
In 2023, the Swiss National Science Foundation (SNSF) provided a total of CHF961 million worth of funding towards research projects.
Switzerland invites 160 delegations to June Ukraine peace talks
This content was published on
Russia is currently not among the delegations invited to talks aimed at helping bring about peace in the conflict between Moscow and Ukraine.
Survey: air travel most popular way to go on holidays for Swiss
This content was published on
Despite the climate crisis, flying is the most popular mode of transport for private travel – particularly among young, urban and high-income travellers.
Swiss government to use phone data to identify asylum seekers
This content was published on
From April 2025, authorities plan to be able to analyse data from mobile phones, computers and other data carriers to identify asylum seekers.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis weighs reinsurance tie-up to fund ultra-expensive drugs
This content was published on
Swiss drugmaker Novartis is exploring working with the global reinsurance industry to help bear the cost of new personalised therapies.
Too few pharma companies prioritise access to medicines
This content was published on
Novartis and Roche both get a boost in the 2018 ranking of progress in expanding access to medicines by the biggest pharmaceutical companies.
This content was published on
Sandoz Inc. and Pear Therapeutics announced that that an app to help treat opium addicts was approved in the United States.
The pharma holy grail: drugs for you, designed by you
This content was published on
In the age of sensors, wearables, and artificial intelligence (AI), almost everything can be customised for the individual.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.